SunTrust Banks, Inc. reiterated their buy rating on shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) in a research note released on Friday. They currently have a $61.00 price objective on the specialty pharmaceutical company’s stock. SunTrust Banks also issued estimates for Supernus Pharmaceuticals’ Q3 2017 earnings at $0.30 EPS and Q4 2017 earnings at $0.24 EPS.

SUPN has been the topic of a number of other research reports. BidaskClub downgraded Supernus Pharmaceuticals from a buy rating to a hold rating in a research note on Wednesday, August 2nd. Jefferies Group LLC restated a buy rating and issued a $51.00 target price on shares of Supernus Pharmaceuticals in a research note on Friday, August 4th. Cowen and Company set a $50.00 target price on Supernus Pharmaceuticals and gave the company a buy rating in a research note on Monday, October 23rd. Janney Montgomery Scott assumed coverage on Supernus Pharmaceuticals in a research note on Friday, July 14th. They issued a neutral rating and a $47.00 target price on the stock. Finally, Stifel Nicolaus restated a buy rating and issued a $47.00 target price (up previously from $36.00) on shares of Supernus Pharmaceuticals in a research note on Tuesday, July 18th. Four research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The stock has a consensus rating of Buy and an average price target of $49.78.

Shares of Supernus Pharmaceuticals (SUPN) traded up $0.55 during midday trading on Friday, reaching $42.05. The company’s stock had a trading volume of 347,083 shares, compared to its average volume of 446,964. The company has a quick ratio of 1.74, a current ratio of 1.94 and a debt-to-equity ratio of 0.01. Supernus Pharmaceuticals has a 1 year low of $17.25 and a 1 year high of $50.04. The stock has a market capitalization of $2,130.00, a P/E ratio of 36.40, a P/E/G ratio of 1.81 and a beta of 1.30.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its earnings results on Wednesday, August 2nd. The specialty pharmaceutical company reported $0.32 EPS for the quarter, beating analysts’ consensus estimates of $0.24 by $0.08. Supernus Pharmaceuticals had a return on equity of 30.73% and a net margin of 41.10%. The firm had revenue of $75.83 million for the quarter, compared to the consensus estimate of $68.54 million. equities research analysts forecast that Supernus Pharmaceuticals will post 1.04 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Supernus Pharmaceuticals, Inc. (SUPN) Given “Buy” Rating at SunTrust Banks, Inc.” was first reported by Watch List News and is owned by of Watch List News. If you are accessing this report on another publication, it was copied illegally and reposted in violation of United States & international copyright law. The legal version of this report can be viewed at https://www.watchlistnews.com/supernus-pharmaceuticals-inc-supn-given-buy-rating-at-suntrust-banks-inc/1678825.html.

In other Supernus Pharmaceuticals news, insider Stefan K.F. Schwabe sold 95,000 shares of the business’s stock in a transaction dated Thursday, September 7th. The stock was sold at an average price of $46.59, for a total value of $4,426,050.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Gregory S. Patrick sold 50,000 shares of the business’s stock in a transaction dated Friday, September 8th. The stock was sold at an average price of $47.60, for a total value of $2,380,000.00. The disclosure for this sale can be found here. Insiders sold 153,709 shares of company stock valued at $7,223,108 in the last ninety days. Insiders own 6.70% of the company’s stock.

Large investors have recently made changes to their positions in the business. Neumeier Poma Investment Counsel LLC lifted its position in shares of Supernus Pharmaceuticals by 1.6% in the second quarter. Neumeier Poma Investment Counsel LLC now owns 890,740 shares of the specialty pharmaceutical company’s stock worth $38,391,000 after buying an additional 14,430 shares during the last quarter. Teachers Advisors LLC lifted its position in shares of Supernus Pharmaceuticals by 6.9% in the second quarter. Teachers Advisors LLC now owns 466,060 shares of the specialty pharmaceutical company’s stock worth $20,087,000 after buying an additional 29,939 shares during the last quarter. Sheets Smith Wealth Management acquired a new position in shares of Supernus Pharmaceuticals during the 2nd quarter worth about $378,000. Royce & Associates LP lifted its position in shares of Supernus Pharmaceuticals by 22.3% during the 2nd quarter. Royce & Associates LP now owns 159,000 shares of the specialty pharmaceutical company’s stock worth $6,853,000 after purchasing an additional 29,000 shares during the last quarter. Finally, Bank of America Corp DE lifted its position in shares of Supernus Pharmaceuticals by 10.7% during the 1st quarter. Bank of America Corp DE now owns 362,952 shares of the specialty pharmaceutical company’s stock worth $11,361,000 after purchasing an additional 35,069 shares during the last quarter. 95.06% of the stock is owned by institutional investors.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Analyst Recommendations for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.